One of the primary factors fueling the growth of the DOACs market is the rapid uptake and expected utilization within the ...

The Progressive Fibrosing Interstitial Lung Disease (PF-ILD) market is currently valued at USD 4,742.2 Million in 2023 and is ...

The Roundup covers notable class action decisions from federal appellate courts and notable Supreme Court class action cert petitions.

Global Thrombocytopenia Treatment IndustryThe global Thrombocytopenia Treatment Market is projected to experience significant ...

Boehringer Ingelheim, Eli Lilly, Moonlake Immunotherapeutics, and Aristea Therapeutics. Sabyasachi Ghosh (Associate Vice ...

The treatment of IBD has evolved significantly over the past 15 years. Historically, steroids and immunosuppressive drugs, such as methotrexate (MTX), azathioprine (AZA) and 6-mercaptopurine (6-MP) ...

A persistent, often progressive, lung disease, COPD results from chronic inflammation that leads to structural changes ...

As of 2018, Boehringer Ingelheim is one of the world's largest pharmaceutical companies, and the largest private one. Headquartered in Ingelheim, it operates globally with 146 affiliates and more than ...

Bayer and Boehringer Ingelheim both had new data on their HER2-targeting small-molecule drugs to present at the World Conference on Lung Cancer (WCLC), hoping to add new oral therapies to the ...

Pierre Cesaro has received grants or consulting fees from Boehringer Ingelheim, Servier, Lundbeck, Novartis, Schering, Biogen, Teva Neuroscience and UCB. Frédérique Grapin is currently an ...

German drugmaker Boehringer Ingelheim has its first regulatory approval for spesolimab, its antibody therapy for rare and life-threatening skin disorder generalised pustular psoriasis (GPP), in ...